Skip to Content

Vemlidy FDA Approval History

FDA Approved: Yes (First approved November 10, 2016)
Brand name: Vemlidy
Generic name: tenofovir alafenamide
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: Hepatitis B

Vemlidy (tenofovir alafenamide) is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.

Development Timeline for Vemlidy

DateArticle
Nov 10, 2016ApprovalFDA Approves Gilead’s Vemlidy (tenofovir alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
Jan 12, 2016Gilead Submits New Drug Application to U.S. FDA for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.